# A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

> **NCT05940532** · PHASE2 · RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Sugemalimab and Chemotherapy

## Key facts

- **NCT ID:** NCT05940532
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2025-01
- **Final completion:** 2026-12
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940532, "A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05940532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*